Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 3/20 | 0.45 |
| ▸ | CES1 | P23141 | 3/20 | 0.45 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | PPARG | P37231 | 6/20 | 0.43 |
| ▸ | PPARD | Q03181 | 6/20 | 0.43 |
| ▸ | PPARA | Q07869 | 6/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propane SCHEMBL322960 | 1.00 | KMT2A (0.48) | KMT2AMAPTCES2CES1HAO1 | |
| Propane SCHEMBL29226175 | 1.00 | KMT2A (0.48) | KMT2AMAPTCES2CES1HAO1 | |
| SCHEMBL16061965 | 0.98 | KMT2A (0.50) | KMT2AMAPTCES2CES1HAO1 | |
| SCHEMBL1720049 | 0.98 | KMT2A (0.50) | KMT2AMAPTCES2CES1HAO1 | |
| Hydrochloric Acid SCHEMBL27720432 | 0.96 | KMT2A (0.48) | KMT2AMAPTCES2CES1HAO1 | |
| Propane SCHEMBL28144123 | 0.90 | FAAH (0.57) | KMT2AMAPTPPARGPPARDPPARA | |
| Propane SCHEMBL741627 | 0.90 | FAAH (0.57) | KMT2AMAPTPPARGPPARDPPARA | |
| Propane SCHEMBL26102539 | 0.89 | FAAH (0.55) | KMT2AMAPTPPARGPPARDPPARA | |
| SCHEMBL2905137 | 0.88 | FAAH (0.58) | KMT2AMAPTPPARGPPARDPPARA | |
| Phosphoric Acid SCHEMBL1223979 | 0.83 | FABP3 (0.54) | KMT2AMAPTPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115513-A1 | METHODS FOR PREPARATION OF PLASMID DNA/LIPID PARTICLES WITH DEFINED SIZE FOR IN VITRO AND IN VIVO TRANSFECTION | THE JOHNS HOPKINS UNIVERSITY | 2024-04-11 | — | — | US | claimed |
| EP-4294450-A1 | METHODS FOR PREPARATION OF PLASMID DNA/LIPID PARTICLES WITH DEFINED SIZE FOR IN VITRO AND IN VIVO TRANSFECTION | The Johns Hopkins University (US) | 2023-12-27 | — | — | EP | claimed |
| CN-108042803-B | Liposome dispersion liquid loaded with AIE molecules and preparation method and application thereof | 国家纳米科学中心 | 2020-06-16 | — | — | CN | claimed |
| EP-2701734-B1 | LIPOSOMAL FORMULATIONS | MOLECULAR EXPRESS INC (US) | 2019-09-25 | — | — | EP | claimed |
| US-10369229-B2 | Methods and compositions for liposomal formulation of antigens and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-06 | — | — | US | claimed |
| US-20180280534-A1 | METHODS AND COMPOSITIONS FOR LIPOSOMAL FORMULATION OF ANTIGENS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-10-04 | — | — | US | claimed |
| US-9931419-B2 | Methods and compositions for liposomal formulation of antigens and uses thereof | MOLECULAR EXPRESS, INC. (US) | 2018-04-03 | — | — | US | claimed |
| US-20170157266-A1 | METHODS AND COMPOSITIONS FOR LIPOSOMAL FORMULATION OF ANTIGENS AND USES THEREOF | MOLECULAR EXPRESS, INC. | 2017-06-08 | — | — | US | claimed |
| US-9364563-B2 | Methods and compositions for liposomal formulation of antigens and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-06-14 | — | — | US | claimed |
| EP-2405758-B1 | METHODS AND COMPOSITIONS FOR LIPOSOMAL FORMULATION OF ANTIGENS AND USES THEREOF | MOLECULAR EXPRESS INC (US) | 2016-04-27 | — | — | EP | claimed |
| US-7390505-B2 | Nanoparticulate topiramate formulations | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2008-06-24 | — | — | US | claimed |
| EP-1663158-A2 | SPECIFIC DELIVERY OF DRUGS TO THE BRAIN | BAXTER INTERNATIONAL INC. (US) | 2006-06-07 | — | — | EP | claimed |
| EP-1628641-A2 | SOLID PARTICLES COMPRISING AN ANTICONVULSANT OR AN IMMUNOSUPPRESSIVE COATED WITH ONE OR MORE SURFACE MODIFIERS | BAXTER INTERNATIONAL INC. (US) | 2006-03-01 | — | — | EP | claimed |
| US-20050244503-A1 | Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents | BAXTER HEALTHCARE S.A. (CH) | 2005-11-03 | — | — | US | claimed |
| US-20050048002-A1 | Dispersion; controlling particle size; preabsorption of drug by cells before administering; transferring to brain | BAXTER INTERNATIONAL INC. | 2005-03-03 | — | — | US | claimed |
| WO-2004112747-A2 | SPECIFIC DELIVERY OF DRUGS TO THE BRAIN | BAXTER INTERNATIONAL INC. (US) | 2004-12-29 | — | — | WO | claimed |
| EP-1487412-A1 | CHEMOSENSITIZING WITH LIPOSOMES CONTAINING OLIGONUCLEOTIDES | GEORGETOWN UNIVERSITY (US) | 2004-12-22 | — | — | EP | claimed |
| WO-2004103348-A2 | SOLID PARTICLES COMPRISING AN ANTICONVULSANT OR AN IMMUNOSUPPRESSIVE COATED WITH ONE OR MORE SURFACE MODIFIERS | BAXTER INTERNATIONAL INC. (US) | 2004-12-02 | — | — | WO | claimed |
| US-20030215489-A1 | Chemosensitizing with liposomes containing oligonucleotides | GEORGETOWN UNIVERSITY | 2003-11-20 | — | — | US | claimed |
| WO-2003070221-A1 | CHEMOSENSITIZING WITH LIPOSOMES CONTAINING OLIGONUCLEOTIDES | GEORGETOWN UNIVERSITY (US) | 2003-08-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157266-A1 | METHODS AND COMPOSITIONS FOR LIPOSOMAL FORMULATION OF ANTIGENS AND USES THEREOF | DDOST, MAGT1, SGMS2 | KMT2A 1407/4885MAPT 981/4885CES2 3819/4885 |
| US-10369229-B2 | Methods and compositions for liposomal formulation of antigens and uses thereof | DDOST, MAGT1, SGMS2 | KMT2A 1407/4885MAPT 981/4885CES2 3819/4885 |
| US-20180280534-A1 | METHODS AND COMPOSITIONS FOR LIPOSOMAL FORMULATION OF ANTIGENS AND USES THEREOF | DDOST, MAGT1, SGMS2 | KMT2A 1407/4885MAPT 981/4885CES2 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.